Document is current
Any future updates will be listed below
-
Authors
Haeussler, Katrin https://orcid.org/0000-0002-3236-2028
Ismaila, Afisi S. https://orcid.org/0000-0002-2876-8308
Malmenäs, Mia https://orcid.org/0000-0002-2625-9198
Noorduyn, Stephen G. https://orcid.org/0000-0002-5936-5579
Green, Nathan https://orcid.org/0000-0003-2745-1736
Compton, Chris https://orcid.org/0000-0002-7564-5343
Thabane, Lehana https://orcid.org/0000-0003-0355-9734
Vogelmeier, Claus F. https://orcid.org/0000-0002-9798-2527
Halpin, David M. G. https://orcid.org/0000-0003-2009-4406
- License Information
-
More Information
Article History
Received: 4 July 2024
Accepted: 28 November 2024
First Online: 21 December 2024
Declarations
:
: Not applicable.
: Not applicable.
: KH and MM are employees of ICON PLC. ASI, SGN, and CC are employees of and/or hold financial equities in GSK. ASI is also a part-time, unpaid professor at McMaster University. NG is part-funded by ICON PLC. LT has worked as a paid consultant or served as a board member for the following companies: Bausch Health, GSK, Baxter, Teva Pharmaceuticals, and Theralase Inc. He also works as Vice-President Research for St Joseph's Healthcare Hamilton. CFV has given presentations at symposia and/or served on scientific advisory boards sponsored by Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, Insmed, MedUpdate, Menarini, Novartis, Nuvaira, Roche, and Sanofi. DMGH reports personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Chiesi, CSL Behring, GSK, Inogen, Menarini, Novartis, Pfizer, and Sanofi.
